SIRT1 and cancer: This regulatory axis can be further strengthened by supplementation with NAD+ precursors, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which elevate intracellular NAD+ levels and consequently augment SIRT1 activity, reinforcing redox balance and resistance to senescence in cancer cells [34].